Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham P Collins

Showing results (121-130 of 164) with videos related to

Pageof 17
Sort By:
Blood Advances|November 23, 2020
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysisAriela Noy, Sven de Vos, Morton Coleman, et al.
Hemasphere|December 13, 2021
A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory LymphomaGraham P Collins, Toby A Eyre, Debora Schmitz-Rohmer, et al.
Future Oncology (London, England)|December 10, 2025
Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphomaNathalie A Johnson, Pier Luigi Zinzani, Eva Domingo-Domenech, et al.
Hematological Oncology|August 7, 2019
A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCLToby A Eyre, Catherine Hildyard, Angela Hamblin, et al.
The New England Journal of Medicine|November 1, 2018
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's LymphomaRanjana Advani, Ian Flinn, Leslie Popplewell, et al.
Blood Advances|March 26, 2024
Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphomaPier Luigi Zinzani, Gilles Salles, Alison J Moskowitz, et al.
Blood|April 21, 2024
Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trialSridhar Chaganti, Shanna Maycock, Graham McIlroy, et al.
British Journal of Haematology|July 6, 2016
NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndromeToby A Eyre, Ruth Clifford, Adrian Bloor, et al.
Hemasphere|June 14, 2024
Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysisMaeve A O'Reilly, William Wilson, David Burns, et al.
Blood Advances|August 2, 2023
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 studyStephen M Ansell, Paul J Bröckelmann, Gottfried von Keudell, et al.
Pageof 17

Showing results (121-130 of 164) with videos related to

Sort By:
Pageof 17
Blood Advances|November 23, 2020
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysisAriela Noy, Sven de Vos, Morton Coleman, et al.
Hemasphere|December 13, 2021
A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory LymphomaGraham P Collins, Toby A Eyre, Debora Schmitz-Rohmer, et al.
Future Oncology (London, England)|December 10, 2025
Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphomaNathalie A Johnson, Pier Luigi Zinzani, Eva Domingo-Domenech, et al.
Hematological Oncology|August 7, 2019
A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCLToby A Eyre, Catherine Hildyard, Angela Hamblin, et al.
The New England Journal of Medicine|November 1, 2018
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's LymphomaRanjana Advani, Ian Flinn, Leslie Popplewell, et al.
Blood Advances|March 26, 2024
Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphomaPier Luigi Zinzani, Gilles Salles, Alison J Moskowitz, et al.
Blood|April 21, 2024
Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trialSridhar Chaganti, Shanna Maycock, Graham McIlroy, et al.
British Journal of Haematology|July 6, 2016
NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndromeToby A Eyre, Ruth Clifford, Adrian Bloor, et al.
Hemasphere|June 14, 2024
Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysisMaeve A O'Reilly, William Wilson, David Burns, et al.
Blood Advances|August 2, 2023
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 studyStephen M Ansell, Paul J Bröckelmann, Gottfried von Keudell, et al.
Pageof 17